Australia: Infrastructure and Innovations for Clinical Trials

Sponsors seeking venues for pharmaceutical research and development would do well to consider Australia – offering a highly favorable, stable environment and experienced, capable local expertise. This article is the second in a three-part series: Here, we examine the landscape for clinical trials, including infrastructure, government funding support and incentives, patient centricity, patient recruitment, and the adoption of innovation.

Interested in more? Check out part 1 and part 3.


Open PDF

Return to Insights Center

Related Insights

Blog

Adapting the validation process for PROs for rare diseases and other diseases with large unmet need and/or rapid progression

Apr 23, 2024

Article

Australia: The Regulatory and Reimbursement Environment

Aug 28, 2023

Article

Decentralized clinical trials - A more patient-centric approach

May 10, 2021

Blog

Decentralized Trials: Considerations for Building a New Patient-Centric Model

May 13, 2021

Blog

A patient-centric approach to managing clinical trial complexity

Jul 13, 2021

Blog

Highlights from ISMPP Asia Pacific Meeting 2021

Sep 20, 2021

Video

Part 2: Risk-based Quality Management Video (RBQM) Series

Nov 11, 2021

Podcast

Decentrally Speaking | Episode 3: Integrating the Patient Voice into Decentralized Trials

Jul 28, 2022

Blog

Including patients in DCT design

Sep 13, 2022

Video

The FDAs Race and Ethnic Diversity Plan Guidance: How prepared is your organization?

Feb 1, 2023

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023